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Virinder Kaur Sarhadi3, Sakari Knuutila3, Johan Lundin1,4, peter Horvath1,5 & 
emmy W. Verschuren  1*
to facilitate analysis of spatial tissue phenotypes, we created an open-source tool package named 
‘Spa-RQ’ for ‘Spatial tissue analysis: image Registration & Quantification’. Spa-RQ contains software 
for image registration (Spa-R) and quantitative analysis of DAB staining overlap (Spa-Q). it provides 
an easy-to-implement workflow for serial sectioning and staining as an alternative to multiplexed 
techniques. to demonstrate Spa-RQ’s applicability, we analysed the spatial aspects of oncogenic 
KRAS-related signalling activities in non-small cell lung cancer (nScLc). Using Spa-R in conjunction 
with ImageJ/Fiji, we first performed annotation-guided tumour-by-tumour phenotyping using multiple 
signalling markers. This analysis showed histopathology-selective activation of PI3K/AKT and MAPK 
signalling in Kras mutant murine tumours, as well as high p38MAPK stress signalling in p53 null murine 
nScLc. Subsequently, Spa-RQ was applied to measure the co-activation of MApK, AKt, and their 
mutual effector mTOR pathway in individual tumours. Both murine and clinical NSCLC samples could 
be stratified into ‘MAPK/mTOR’, ‘AKT/mTOR’, and ‘Null’ signature subclasses, suggesting mutually 
exclusive MAPK and AKT signalling activities. Spa-RQ thus provides a robust and easy to use tool that 
can be employed to identify spatially-distributed tissue phenotypes.
Epithelial cells are locally influenced by neighbouring stromal cells and secreted molecules, as well as tissue gradi-
ents in oxygenation and mechanical forces1,2. During carcinoma progression, such factors contribute to microen-
vironmental heterogeneity which, in conjunction with tumour cell-intrinsic genetic and molecular heterogeneity, 
fosters tumour evolution and compromises treatment success3–5. Tumour heterogeneity can be interrogated by 
gene-centric methods, such as multi-regional or single cell spatial sequencing, or by phenotypic assays, such as 
high-content in vitro imaging or tissue profiling using immunohistochemistry (IHC) analyses. Recent advances 
in multiplexed staining techniques have deepened our understanding of spatial phenotypes at tissue levels and 
yielded data with clinical relevance6–8. Although powerful in principle, practical factors limit flexible implementa-
tion of multiplexed strategies, including availability of specific antibodies of varying host species or signal unmix-
ing accuracy. No such issues exist for the staining of serial sections using standard IHC. However, this requires 
image analysis software that integrates image registration, annotation, and spatial signal quantification.
NSCLC accounts for 85% of all lung cancers and constitutes a heterogeneous set of diseases with complex 
genomic landscapes9,10. Therapies targeting mutations in the EGFR and ALK proteins are available, but these 
mutations are only detected in a small portion of NSCLCs11. Personalised medicine efforts currently focus 
on the identification of sample-specific drug sensitivities, or synergistic combinatorial strategies. However, 
drug-response studies are mostly done in vitro using biochemical means following extrinsic modulation, despite 
the knowledge that oncogenic functions are dynamically and spatially regulated within tumours. Furthermore, 
the oncogenic signalling landscapes of tumours or cancer cell lines are typically characterised by genetic 
1Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, 00014, Finland. 2Single-Cell 
Technologies Ltd, Szeged, Hungary. 3Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, 
Finland. 4Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. 5Synthetic and Systems 
Biology Unit, Hungarian Academy of Sciences, Biological Research Center, Temesvári körút 62, 6726, Szeged, 
Hungary. *email: emmy.verschuren@helsinki.fi
open
2Scientific RepoRtS |         (2019) 9:17613  | https://doi.org/10.1038/s41598-019-54038-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
profiling12 or mass spectrometry-based multi-omics analysis13, while the spatial aspects of networked oncogenic 
activities in native tumour tissues remain understudied.
The PI3K/AKT and MAPK pathways are frequently activated in cancers, including KRAS mutant NSCLCs, 
and around 30% of adenocarcinomas (ACs) and 3% of squamous cell carcinomas (SCCs) contain KRAS muta-
tions14. By using NSCLC tumours from genetically engineered mouse models (GEMMs) driven by KrasG12D 
expression together with loss of Lkb1 (KrasG12D; Lkb1fl/fl, hereafter called KL) or p53 (KrasG12D; p53fl/fl, hereafter 
called KP), we previously demonstrated that NSCLC histopathologies exhibit differences in oncogenic signalling 
activities15. We further showed that an increased spatial overlap of phosphorylated ERK and 4EBP1, respec-
tively marking MAPK and mTOR pathway activities, was associated with increased cytotoxic response towards 
co-inhibition of these pathways in murine tumour slice explants15. This highlights that baseline oncogenic sig-
nalling phenotypes in tumour tissues may inform on drug sensitivity. Hence, we created a Spatial tissue analysis 
tool package for image Registration and Quantification, called ‘Spa-RQ’, to enable image alignment and quantita-
tive examination of spatial tissue phenotypes detected by standard histochemical 3,3’-diaminobenzidine (DAB) 
staining of adjacent tissue sections. This study describes the features of the Spa-RQ tool package, and demon-
strates how its implementation permits dissection of the spatial oncogenic signalling profiles of native murine 
and human NSCLC samples.
Results
introduction of the Spa-RQ software tool package. The Spa-RQ tool package was designed for spatial 
phenotyping on stained serial sections, as an easy-to-implement alternative to multiplexed strategies. It con-
tains an image registration program named ‘Spa-R’, and a DAB quantification program named ‘Spa-Q’ (Fig. 1a). 
Spa-RQ is open-source, compatible with both Windows and Mac systems. In comparison to other open-source 
methods/software that operate on whole slide scans of serial sections16–18, it uniquely combines multiple image 
processing functions with a capacity to perform spatial analysis in selected regions-of-interest (ROIs).
Spa-R iteratively applies a similarity transformation method (the MATLAB® function imregtform) for image 
registration. It can be used to either register pairs or batches of input images in a variety of formats, including 
TIFF, JPEG or PNG, ranging from MB to GB in size. Image registration using Spa-R can be applied to a wide 
range of image captures, and generates newly registered uncompressed TIFF images as output (Fig. 1b). The 
iteration rate of the registration process can be manually adjusted, dependent on precision vs. processing speed 
considerations for a registration case (Fig. 1c). While selective additional parameters can be tested for registration 
optimization using Spa-R_optimizer (Supplementary Fig. S1a,b), Spa-R’s entire codebase is provided to enable 
computational optimization on registration tasks. A comparison of parameter optimization relative to the default 
settings, used for the registration of large >500 MB images, shows that the number of iterations is the major factor 
determining registration quality relative to registration speed (Supplementary Fig. S1d), while other factors have 
either less (PyramidLevels and InitialRadius; Supplementary Fig. S1c,e) or no effect (Epsilon and GrowthFactor; 
Supplementary Fig. S1f,g). Spa-R can be installed on multiple computers, and can thus be run in parallel with 
Spa-Q for optimal efficiency.
The Spa-Q image analysis program measures the areas (%) of two individual DAB signals and the area (%) of 
their overlap (OL). It is easy to operate and suitable for researchers with limited image analysis expertise. The con-
trol panel of Spa-Q includes multiple image processing modules, specifically (i) image selection, (ii) ROI creation/
selection, and (iii) thresholding-based segmentation of tissue areas (binary thresholding), hematoxylin (segmen-
tation of nuclei) and DAB-stained areas (Fig. 1d). Following image processing, the results folder is automatedly 
loaded with segmented images and an Excel sheet that lists the raw signal quantification results (percentages of 
individual DAB-stained areas, and area of OL per ROI). In addition, a pseudo-coloured mask depicting the two 
individual stainings in yellow and orange, and their OL area in red, is generated (Fig. 1e).
The next sections describe two proof-of-concept applications of the Spa-RQ tool package. In the first, Spa-R 
was used in conjunction with ImageJ/Fiji19 to perform annotation-guided quantification of multiple stainings on 
serial tissue sections (Application 1 in Fig. 1f). In the second application, Spa-RQ was used to quantify the spatial 
co-expression of two signalling markers, detected by staining on neighbouring tissue sections (Application 2 in 
Fig. 1f). Another possible application, not introduced here, is for re-alignment or quantification of multiplexed 
images (Application 3 in Fig. 1f). Importantly, Spa-RQ’s source code is freely available, and can be modified to 
match the user’s needs, for example to enable the quantitative analysis of fluorescent signals.
Using Spa-R for NSCLC histopathology-selective lesion profiling. The expression of oncogenic Kras 
together with loss of Lkb1 or p53 in murine lung progenitor cells gives rise to a spectrum of NSCLC lesions of 
different histopathologies20,21. These mice develop multiple tumours in the lungs, each marked by distinguishable 
histological features (Fig. 2a). We set out to use Spa-R to quantify NSCLC histopathology-selective oncogenic 
signalling activities, with primary focus on the PI3K/AKT, MAPK, and mTOR pathways, as well as the p38MAPK 
stress-sensing pathway (Fig. 2b). To achieve this, Spa-R was used to register DAB-stained images to their closest 
H&E reference (Fig. 2c). Registered DAB images were subsequently overlaid with the ROI mask generated by 
annotating the H&E references using ImageJ/Fiji, to permit quantification of DAB signal per ROI with ImageJ/
Fiji (Fig. 2d).
Lesions of the three most common histopathology types in KL and KP GEMMs, namely adenosquamous 
carcinoma (ASC), confined to KL mice, as well as papillary adenocarcinoma (PAC) and invasive adenocarcinoma 
(IAC) (Fig. 2e) were subjected to quantification of p4EBP1 (marking mTOR), pAKT (marking AKT), pERK 
(marking MAPK), and pp38 (marking p38MAPK) expression (Fig. 2f, Supplementary Fig. S2a). As reported15, 
phosphorylation of AKT was detected in ASCs but absent in PACs and IACs (P value < 0.0001). Furthermore, 
pERK expression was significantly higher in PACs than in IACs, suggesting differential MAPK regulatory pheno-
types in these two AC subtypes (KL-PAC vs KL-IAC, individual tumours P value < 0.0001, grouped by animal P 
3Scientific RepoRtS |         (2019) 9:17613  | https://doi.org/10.1038/s41598-019-54038-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
value = 0.001; KP-PAC vs KP-IAC, individual tumours P value < 0.0001, grouped by animals P value = 0.0135). 
MAPK signalling was activated more widely in PACs than ASCs (individual KL-PAC vs ASC P value = 0.0024, 
grouped by animals P value = 0.0257) (Fig. 2f,g, Supplementary Fig. S2a). p4EBP1 expression, on the other 
hand, was variable from lesion to lesion, showing no significant differences between the three histopathologies 
(Fig. 2f,g). Thus, NSCLC subtype-selective oncogenic signalling signatures were observed, with ASCs marked 
as ‘AKTpositive/MAPKlow-medium’, PACs as ‘AKTnegative/MAPKmedium-high’ and IACs as ‘AKTnegative/MAPKlow-medium’. 
Interestingly, p38MAPK phosphorylation was found to be genotype-selective, showing pathway activation 
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Figure 1. An introduction to the Spa-RQ software tool package. (a) Schematic overview of Spa-RQ, which 
includes software for image registration (Spa-R) and spatial quantification (Spa-Q). (b) Examples of image 
sets that can be registered by Spa-R. (c) Upper image panel illustrates the alignment outcomes following Spa-R 
implementation with different iteration numbers. The registration quality increases with the iteration number, 
which can be set by users. The lower bar plot shows how the time required for Spa-R registration increases with 
image size and iteration number. An iteration rate of 100 is recommended to register images on neighbouring 
4 µm tissue sections. (d) Overview of the control panel of Spa-Q. A detailed User Manual can be found in the 
software folder at the official repository. (e) Examples of outputs generated by Spa-Q. For each ROI, a coloured 
overlay mask is provided in conjunction with an Excel file listing image quantification data. (f) Overview of 
various image modalities to which Spa-RQ can be applied.
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Figure 2. Implementation of Spa-R to analyse oncogenic signalling activities in murine NSCLC 
histopathologies. (a) Schematic overview depicting FFPE lung tumour tissue block preparation from 
KrasG12D; Lkb1fl/fl (KL) or KrasG12D; p53fl/fl (KP) GEMMs. Multiple tumours arise in the lung lobes of an 
individual GEMM. (b) Diagram illustrating oncogenic signalling pathways regulated by KRAS and LKB1 or 
p53. Solid arrows indicate direct regulation. (c) Schematic overview showing the order of H&E- and DAB-
stained tissues sections for image registration. (d) Diagram showing an example image analysis workflow 
using Spa-R for registration and ImageJ/Fiji for annotation and quantification. The former is used to align 
DAB images to H&E images, the latter is used to generate annotations and perform ROI-guided quantification 
of DAB signal on each of the registered images. Red outlines on DAB images are original overlays from 
H&E-based annotations; green outlines are adjusted overlays due to the distance between tissue sections 
stained with different antibodies. (e) Graphical representation of the numbers of NSCLC lesions of different 
histopathologies in 9 KL and 5 KP GEMMs. In mixed ACs (adenocarcinomas) multiple histological features 
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specifically in KP tumours (Fig. 2f,g). Implementation of Spa-R as an image pre-processing step is thus shown 
to achieve ROI-guided staining quantification, and identifies oncogenic signalling phenotypes characteristic for 
ASC, PAC, and IAC NSCLC histopathology types.
Using Spa-RQ to visualise and quantify the spatial features of phosphoprotein signals in murine 
nScLc tumours. Our previous findings linked the extent of spatial co-activation of mTOR and MAPK path-
ways to their combinatorial inhibitory response in slice explants15. We hence wished to demonstrate the use of 
Spa-RQ in measuring the spatial co-activation of signalling pathways to dissect histopathology-selective phe-
notypes. Spa-RQ was applied to measure the expression of pERK, pAKT, p4EBP1, and their mutual areas of OL 
(marking MAPK-mTOR co-activation and AKT-mTOR co-activation respectively) in individual murine ASC 
lesions (Fig. 3a). Using a cut-off of >15% OL of pERK and p4EBP expression, as was used in15, Spa-RQ analysis 
showed 2 of 19 ASCs to have a ‘MAPK/mTOR’ signature (ASC_OL; pERK/p4EBP1 > 15%). This is lower than 
found before (4 out of 9 ASCs in15), indicating that quantification of manually-drawn stained area masks, as 
was done previously, can overestimate spatial biomarker quantification compared with intensity-based signal 
segmentation as done here. Additionally, 2 of 19 ASCs were shown to have an ‘AKT/mTOR’ signature (ASC_OL; 
pAKT/p4EBP1 > 15%). The remaining (15/19) ASCs were classified as having a ‘Null’ signature (Fig. 3b). Lesions 
never carried both ‘MAPK/mTOR’ and ‘AKT/mTOR’ signatures (Fig. 3b), indicating mutual exclusivity, con-
sistent with the low OL of pERK and pAKT expression in ASC tumours (Fig. 3c). ‘MAPK/mTOR’ and ‘Null’ 
signature tumours co-existed in animals #3 and 6, indicating inter-tumour signature heterogeneity. We similarly 
analysed the spatial co-activation of the MAPK and mTOR pathways in AKTnegative/MAPKmedium-high papillary 
adenocarcinoma (PAC) tumours, which showed that PACs either classified as ‘MAPK/mTOR’ (PAC_OL; pERK/
p4EBP1 > 15%) or as ‘Null’ signature tumours, again indicating inter-tumour signalling heterogeneity within 
this histopathology group (Supplementary Fig. S2b,c). Taken together, quantitative analysis of signalling OL with 
Spa-RQ revealed that murine NSCLC lesions subclassify based on the levels of spatial MAPK/mTOR or AKT/
mTOR co-activation.
Finally, we applied Spa-RQ to investigate if there was any evidence of signalling pathway co-activation in 
KP-PACs which showed selectively high p38MAPK activity. Interestingly, high p38 phosphorylation was detected 
specifically in regions showing concomitant MAPK activation (Fig. 3d,e). Indeed, even the small areas showing 
pp38 positivity in KL-PACs were in regions showing high MAPK activity, tentatively suggesting dependency on 
MAPK activation to elicit detectable p38MAPK pathway activation in murine PACs.
Spa-RQ reveals spatial oncogenic phenotypes in clinical nScLc samples. To investigate to what 
extent the histopathology-selective spatial signalling phenotypes detected in murine samples were representative 
of human NSCLC, we used Spa-RQ to analyse a set of clinical samples. We first visually evaluated the positivity 
of MAPK, AKT, mTOR, and p38MAPK activation in TMA panels of clinical ASCs and PACs (Supplementary 
Fig. S3a). As reported in15, AKT activation was seen uniquely in clinical ASCs (5/13), but absent in PACs (0/25). 
However, unlike GEMM tumours, where the % area range of pERK expression was clearly distinguishable 
between ASCs (pERKlow-medium) and PACs (pERKmedium-high), we did not find such signatures in human samples. 
Instead pERKmedium-high ASCs and pERKlow-medium PACs were the most common phenotypes in clinical NSCLCs 
(Supplementary Fig. S3b). Moreover, pp38 positivity was observed in more clinical ASCs (61%) than in PACs 
(40%), differentiating from the selectively high pp38 expression in murine KP-PACs (Fig. 2f,g, Supplementary 
Fig. S3a,b). Therefore, histopathology-selective PI3K/AKT activation, but not MAPK or p38MAPK activation, 
was conserved between murine and clinical NSCLC tumours.
Noting that pERK, pAKT, p4EBP1, and pp38 were spatially expressed also in clinical NSCLC samples 
(Supplementary Fig. S3b), we next wished to explore if spatial measurements with Spa-RQ could identify signal-
ling co-activation signatures selective for clinical NSCLC subtypes. We therefore applied Spa-RQ to investigate 
whether the classification of tumours based on MAPK/mTOR (OL; pERK/p4EBP1) or AKT/mTOR (OL; pAKT/
p4EBP1) co-activation signatures translates to human samples. First, the individual levels and OL expression of 
pERK, p4EBP1, and pAKT were measured on a spot-by-spot manner for each ASC (Fig. 4a). Differently from 
murine tumour analyses, classifications were made according to the dominant phenotypes, as intra-tumour stro-
mal infiltrates and overall decreased areas of staining obviated use of a 15% OL cut-off value. We found that 
human ASCs similarly stratified into the three subclasses identified by murine tumour phenotyping, namely: 
(i) ‘MAPK/mTOR’ signature tumours (ASC_9, 10, 12, 13; 4/13); (ii) ‘AKT/mTOR’ signature tumours (ASC_4, 
6, 8; 3/13); and (iii) ‘Null’ signature tumours (ASC_1, 2, 3, 5, 7, 11; 6/13) (Fig. 4b). Variations were measured in 
the duplicate spots sampled from the same donor blocks, indicating intra-tumour signalling heterogeneity. We 
similarly performed spatial analysis on TMA sections representing 25 clinical PAC samples (Fig. 4c), and con-
firmed that both ‘MAPK/mTOR’ signature (PAC_4,8,18) and ‘Null’ signature tumours were detected in clinical 
PACs. Importantly, of the samples for which the KRAS mutation status is known, no correlation between KRAS 
are found in one tumour. (f) Scatterplot showing areas (%) of p4EBP1 (marking mTOR activation), pAKT 
(marking AKT activation), pERK (marking MAPK activation) and pp38 (marking p38 activation) in individual 
adenosquamous carcinomas (ASCs), papillary adenocarcinomas (PACs), or invasive adenocarcinomas (IACs). 
Statistical analysis: one-way ANOVA multiple comparison (Kruskal-Wallis test, nonparametric test) with 
uncorrected Dunn’s test. (g) Representative images illustrating ASC, PAC, and IAC histological features (H&E 
staining), as well as the stainings of p4EBP1, pAKT, pERK, and pp38 in a histopathology-specific manner. Scale 
bars, 500 µm for KL upper panel (entire) images and KL lower panel H&E image and KP H&E image; 100 µm 
for the others.
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Figure 3. Application of Spa-RQ in phenotyping oncogenic signalling network signatures. (a) Bar plot showing 
the % area of p4EBP1, pERK, pAKT, as well as pERK/p4EBP1 (marking MAPK and mTOR co-activation), 
pAKT/p4EBP1 (marking AKT and mTOR co-activation) and pERK/pAKT (marking MAPK and AKT co-
activation) overlap in individual ASCs from 9 KL mice. Animals no.1–5 were used in the analysis in Fig. 2e–g. 
Animals no. 6–9 are included only in the analysis in Fig. 3. The tumour samples were processed for pAKT, 
pERK, and p4EBP1 spatial analysis. The staining orders were mentioned in detail in Methods section. The 
dashed black line indicates a 15% OL level. (b) Pie chart showing the distribution of analysed ASCs in the 
following three signature subclasses: 1. ‘MAPK/mTOR’ (OL; pERK/p4EBP1 > 15%), 2. ‘AKT/mTOR’ (OL; 
pAKT/p4EBP1 > 15%) and 3. ‘Null’ signature. (c) Examples of ASC tumours showing either a ‘MAPK/mTOR’, 
‘AKT/mTOR’ or ‘Null’ signature. (d) Bar plot showing the pp38 and pERK quantification as well as OL of 
pERK/pp38 (marking MAPK and p38 co-activation) by Spa-RQ in individual PACs grouped per animal. (e) 
Representative landscape images illustrating the spatial distribution of pERK and pp38 in one KL-PAC and one 
KP-PAC, generated by Spa-RQ.
7Scientific RepoRtS |         (2019) 9:17613  | https://doi.org/10.1038/s41598-019-54038-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
mutation and spatial signalling signature was detected (Supplementary Fig. S4a,b). The spatial signalling pathway 
co-activation signatures of murine tumours were also identified in the clinical samples.
Based on the quantitative data as well as the landscape masks provided by Spa-RQ analysis, we observed a 
phenotype of stromal MAPK signature in conjunction with tumour-specific mTOR signalling, in both ‘MAPK/
mTOR’ (ASC_12, 13) and ‘Null’ (ASC_5) signature ASCs (Fig. 4a,b). Furthermore, a heterotypic tumour-stromal 
distribution of MAPK and mTOR pathways was also observed in ‘Null’ signature PAC tumours (Fig. 4c,d). This 
indicates increased signalling heterogeneity in clinical tumours, associated with the heterotypic stromal infiltra-
tion characteristic of clinical tumours.
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Figure 4. Spa-RQ reveals spatial oncogenic phenotypes in NSCLC TMA samples. (a) Scatterplot depicting the 
areas (%) of p4EBP1, pERK, pAKT, as well as pERK/p4EBP1, pAKT/p4EBP1 and pERK/pAKT overlap in 13 
individual clinical ASCs. Each dot represents a TMA spot. Human NSCLC TMA blocks contains 2–3 replicate 
cores, representing two spatially distinct tissue regions, and 2–6 TMA spots per ASC tumour were analysed. 
Bars indicate the average values among the spots within one ASC. (b) Pie chart illustrating the classification of 
ASCs according to mTOR/MAPK/AKT spatial phenotypes. Representative images illustrating the classes shown 
in the pie chart, with exception of the ‘Null’ signature. Tumours labelled with an asterisk* show stromal MAPK 
and tumour-specific mTOR signalling. On landscape mask, OL areas are marked with red colour, yellow and 
orange each present tumour area stained with an individual marker. Scale bar, 500 µm. (c) Scatterplot showing 
the expression of p4EBP1 and pERK, as well as their OL in 25 clinical PAC samples. Each dot represents a TMA 
spot, and 2–4 spots representing spatially distinct tissue regions per PAC sample were included in the analyses. 
Bars indicating the average value of spots for individual PAC. (d) Representative images of PAC TMA samples 
showing a tumour-specific ‘MAPK/mTOR’ signature or stromal MAPK/epithelial tumour mTOR signature. 
Scale bar, 500 µm.
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Finally, we also explored the spatial activation of p38MAPK signalling in clinical samples, and asked if p38 
phosphorylation was detected in conjunction with high pERK expression, as was the case in murine PACs. Of 
the eight pp38positive ASCs, four contained a ‘MAPK/mTOR’ signature, and only one of these (ASC_9, pERKh-
igh) showed spatial co-activation of MAPK and p38MAPK signalling. In addition, three pp38positive ASCs con-
taining an ‘AKT/mTOR’ signature (ASC_4, 6, 8) showed pp38 staining in pAKT positive areas (Supplementary 
Fig. S3c). In clinical PACs, the co-activation of MAPK and p38MAPK was observed in only one out of ten 
pp38positive tumours (PAC_4, ‘MAPK/mTOR’ signature) (Supplementary Fig. S3d). Thus, the spatial p38MAPK 
and MAPK co-activation phenotype of clinical samples was more heterogeneous than in murine samples. In 
conclusion, implementation of Spa-RQ can classify both murine and clinical NSCLCs based on distinct signal-
ling co-activation signatures, and reveals that histopathology-selective PI3K/AKT activity in ASC tumours is 
conserved between species. However, the more pronounced molecular and heterotypic stromal heterogeneity of 
human NSCLCs adds complexity to straightforward phenotype-based disease stratification.
Discussion
We introduce a software package named Spa-RQ to visualise and quantify the spatial features of markers detected 
by standard IHC on serial tissue sections. This package is easy to operate and visualises the spatial data as an 
attractive landscape. Spa-RQ consists of the Spa-R program for image registration and the Spa-Q program for 
spatial image analysis in multiple ROIs on IHC images. Image registration is a much anticipated method develop-
ment field, and sophisticated algorithms are required for lower resolution medical images or for motion correc-
tion22,23. However, the histological images in our study are applied to serial sections of tissues with near-identical 
architecture, and stained with standardised protocols. A similarity transformation with mutual information 
registration method therefore have satisfied all our tests and is used in Spa-R. This image pre-processing step 
enables spatial analysis, e.g. using Spa-Q or ImageJ/Fiji, at the tissue level. Both of these apply simple signal 
intensity-based quantification methods, necessitating an inter-observer study to set thresholds. Implementation 
of Spa-RQ for the phenotypic profiling on any set of DAB-stained slides can help discover native tissue pheno-
types, and generate hypotheses for further investigation. Spa-RQ is open-source software and can be further 
modified based on the user’s needs, for example: to quantify spatial co-expression of more than two markers; or 
to add segmentation modules for spatial analysis at single-cell resolution.
As proof-of-concept demonstrations of Spa-RQ, we first combined use of Spa-R and ImageJ/Fiji to analyse 
the signalling activities in NSCLC lesions of different histopathologies. This corroborated our previous iden-
tification15 of histopathology-selective signalling signatures, reflecting the diverse roles of signalling networks 
in oncogenic transformation. Specifically, we found that Kras mutant murine ASCs, PACs, and IACs were clas-
sified as AKTpositive/MAPKlow-medium, AKTnegative/MAPKmedium-high, and AKTnegative/MAPKlow-medium, respectively, 
and that the PAC and IAC signatures were independent of the KL and KP driver mutations. Similar to the 
murine sample data, clinical PACs also showed absence of AKT signalling, suggesting that signalling mecha-
nisms driving histopathology-selective lesion progression may in part be conserved across species. Functional 
studies with lung cancer cell lines have similarly demonstrated that MAPK versus PI3K/mTOR dependency 
can stratify KRAS-driven cancers24, and an interesting outstanding question remains how this may relate to 
histopathology-selective pathway dependencies.
In the second proof-of-concept application, we applied Spa-RQ as a spatial analysis tool to demonstrate how 
oncogenic signalling pathway co-activation can be examined in individual tumours. The MAPK and PI3K/AKT 
pathways have multiple downstream effectors, including mTOR pathway activation, which have major roles in 
tumourigenesis, disease prognosis, and therapeutic response25,26. ASC tumours showed heterogeneity in MAPK, 
AKT, and mTOR pathway activities, and were stratified into three mutually exclusive subclasses, namely ‘MAPK/
mTOR’, ‘AKT/mTOR’, and ‘Null’. Minimal co-activation of the MAPK and AKT pathways was observed, which 
is consistent with the known negative feedback regulation of MAPK activity by AKT27. Similarly, NSCLC PACs 
were divided into ‘MAPK/mTOR’ and ‘Null’ tumours. Importantly, the same tumour subclasses were observed 
in human samples, indicating cross-species conservation. In some clinical samples, clear stromal MAPK activity 
could be detected, in accordance with the increased stromal component in human disease compared to murine 
tumours. The detection of signalling heterogeneity in tumours carrying identical driver mutations matches a 
previous report demonstrating PI3K/MAPK heterogeneity in PIK3CA mutant breast cancer, a rare example of 
a study applying multiplexed techniques to investigate phosphoprotein networks28. An interesting question for 
future mechanistic exploration is whether such spatial phenotyping of in situ signalling heterogeneities can fur-
ther refine the predictive stratification of tumours linked to drug response.
Contrary to the histopathology-selective MAPK and AKT activation patterns, p38MAPK activation was 
found to be associated with p53 loss-of-function in murine NSCLC. This is potentially explained by increased 
ATM/ATR-mediated phosphorylation of p38 in p53 null cells, known to promote cell survival following DNA 
damage29. Corroborating this, a more recent study showed that activation of p38MAPK has an active role in 
DNA repair by phosphorylation of CtIP25, together suggesting that the increased p38MAPK signalling relates to 
compromised DNA integrity of p53 null tumours. Interestingly, we found that p38 phosphorylation was particu-
larly pronounced in murine tumour regions with high MAPK activity, implying context-dependent co-activation 
of p38MAPK and MAPK pathways following DNA damage or other stress mechanisms. However, in clinical 
samples, p38MAPK activation was not clearly associated with increased MAPK activity, consistent with a more 
intricate molecular evolutionary diversity of clinical samples, compromising simple correlations.
To conclude, Spa-RQ is a simple and robust image analysis tool that, when combined with a serial section 
staining strategy, facilitates the identification of spatial tissue phenotypes. Application of the software in the anal-
ysis of oncogenic signalling can help to dissect inter- and intra-tumour phenotypic heterogeneity. Once linked 
to drug response studies, such spatial phenotyping approaches may have the potential to expose biomarkers of 
drug sensitivity.
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Methods
Human and murine tumour tissues. Breeding of KL and KP mice, and lung tumour initiation, were 
performed as described21. Animal handling and studies were performed according to the guidelines from Finnish 
National Board of Animal Experimentation, and they were approved by the Experimental Animal Committee 
of the University of Helsinki and the State Provincial Office of Southern Finland (ESAVI/857/04.10.07/2013). 
Formalin fixed paraffin embedded (FFPE) samples of human NSCLC ASC and PAC lesions were collected from 
the Helsinki Biobank’s pathology sample archive (Helsinki Biobank project number HBP2016002). A TMA was 
constructed from the FFPE samples. Surgically resected tumour specimens were received from NSCLC patients, 
with informed consent, at the Hospital District of Helsinki and Uusimaa (HUS), as approved by the ethical board 
of the Joint Authority for the HUS, Finland (Dnro: 85/13/03/00/15). Experimental procedures on human tumour 
tissues were performed in accordance with the guidelines and regulations in the acquired ethical permission. 
Detailed information and raw data from the murine and human NSCLC sample analyses is provided in the 
Supplementary Table S1.
tissue processing, sectioning and staining order. Murine lung tumours were processed as described15. 
FFPE tissue blocks containing whole murine lung or clinical NSCLC TMA samples were cut as 4 µm thick sec-
tions. Two sequential sections were placed on one glass slide (SUPERFROST ® PLUS, Thermo scientific, Ref 
J1800AMNZ), and labelled to mark the sectioning order. Adjacent tissue sections were each stained with one 
antibody from a defined series of sequential antibodies. For murine samples in Figs. 2e,g and 3a GEMM No. 1–5, 
stainings and tissue sections were as follows: 1-p63, 2-NKX2.1, 5-HE, 6-p4EBP1, 9-pAKT, 10-pERK, 11-pp38 
and 14-HE. Thus, p4EBP1- and pAKT-stained sections were 12 µm apart, and p4EBP1- and pERK-stained sec-
tions were 16 µm apart; H&E-stained sections were 4–16 µm apart from various DAB-stained sections; pAKT-, 
pERK-, and pp38-stained sections were consecutive. For the additional GEMM tumour samples included in 
Fig. 3a GEMM No.6–9, pAKT, p4EBP1 and pERK were stained on consecutive tissue sections. For the TMA 
analyses, the staining order was: 1-pERK, 2-pp38, 3-pAKT and 4-p4EBP1.
immunohistochemistry (iHc) and image acquisition. Standard IHC was performed as described15. 
To achieve consistency in hematoxylin and DAB signals, IHC was simultaneously performed on all samples in 
the following groups: 1. murine samples used in Figs. 2 and 3 (No. 1–5 in Fig. 3a); 2. samples from animals 6–9; 
3. TMA panels of clinical samples.
The following antibodies were used for IHC: rabbit anti-TTF1 (NKX2.1) (Abcam 133638; 1:2000), rabbit 
anti-p63 (Abcam ab124762; 1:10000), rabbit anti-E-cadherin (Cell Signalling Technology CST 3195; 1:400), rabbit 
anti-phospho-AKT for murine samples (Cell Signalling Technology CST4058; 1:400), rabbit anti-phospho-AKT 
for clinical samples (Cell Signalling Technology CST4060; 1:300), rabbit anti-p44/22 (Erk1/2) (Cell Signalling 
Technology CST4370; 1:1000 for murine samples; 1:500 for TMA samples), rabbit anti-p4EBP1 (CST2855, 
Cell Signalling Technology; 1:1000), rabbit anti-pp38 (Cell Signalling Technology CST4511; 1:200). For all 
the antibodies, antigen retrieval was done using 10 mM sodium citrate pH 6.0. All antibodies except p4EBP1 
were incubated 1.5 h at room temperature; p4EBP1 antibody was incubated overnight at 4 °C. BrightVision 
poly-horseradish peroxidase goat anti-rabbit IgG (Immunologic, Duiven, The Netherlands) was incubated at 
room temperature for half an hour and Bright-DAB Substrate Kit (Immunologic, Duiven, The Netherlands) were 
used for detection.
Stained murine lung sections were scanned with a Cytation™ 5 Cell Imaging Multi-Mode Reader using a 
10x objective, and stored as TIFF images. Whole slide scans of stained clinical TMA sections were acquired by a 
Pannoramic 250 3DHISTECH digital slide scanner using a 20x objective. TIFF images of individual TMA spots 
were exported using the Pannoramic Viewer (3DHISTECH Ltd) at a magnification of 1:2. Histopathology classi-
fication was performed as done previously15,21, in conjunction with an expert pathologist.
Software development. Spa-RQ was written in MATLAB® (The MathWorks, Inc. USA). It is freely distrib-
uted at https://bitbucket.org/MagoBitbucket/spa-rq-tools as an open-source tool, where users can read the gen-
eral description and license; they can also go to ‘Source’ to view or use the source code, or ‘Downloads’ to access 
Mac or PC versions of Spa-RQ, where a User Manual is included. For the registration algorithm, the MATLAB® 
function imregtform was used (https://se.mathworks.com/help/images/ref/imregtform.html). Spa-R iteratively 
applies a similarity transformation method for image registration. This uses a multimodal image input to com-
pute an initialization for the registration metric as well as an optimizer configuration. This metric is defined by 
the maximization of the mutual information between the reference image and the image(s) to be aligned. The 
optimisation runs to a maximum number of iterations, or until it converges. While default parameters are used in 
Spa-R (e.g. InitialRadius = 0.0018, PyramidLevels = 3, Epsilon = 1.5e-06, and GrowthFactor = 1.05), we created 
Spa-R_optimizer to allows users to manually adjust all five parameters (https://bitbucket.org/MagoBitbucket/
spa-rq-tools). Spa-Q performs colour decomposition with two vectors, one for Hematoxylin staining and the 
other for DAB. Colour decomposition matrix [0.650 0.704 0.286] is used for Hematoxylin, and [0.072 0.954 
0.283] for DAB. This matrix was obtained via colour deconvolution analysis using the ImageJ/Fiji plugin30.
ROI-specific image analysis with ImageJ/Fiji. ImageJ/Fiji (https://fiji.sc) was used to generate annota-
tions: First, regions-of-interest (ROIs), in this case individual lesions on murine lung lobes, were each outlined 
manually with the polygon tool on H&E images. Secondly, polygons were added to the ROI manager (ImageJ/
Fiji- > Analyse- > Tools > ROI manager), and named according to their histopathology classification. Third, the 
ROI manager for each sample was saved as a Zip file in the sample image folder. Finally, to apply the ROI library 
on DAB images in the image set of one tissue block, both the registered images and the ROI manager were opened 
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in ImageJ/Fiji, and ROIs overlaid on images by selecting the “show all” function in the ROI manager. If necessary, 
polygons were adjusted on new images, and adjusted ROI managers saved.
For image analyses using ImageJ/Fiji, the ROI managers were first applied to each image, followed by colour 
deconvolution to obtain pure DAB masks (ImageJ/Fiji- > Color- > Color Deconvolution- > Vector: H DAB). The 
threshold for each staining was set as the average threshold values of analyses performed by three independent 
immunohistochemical experts, on multiple ROIs. Identical thresholds for each individual staining were applied 
to all samples (Supplementary Table S1). Identical thresholds for each individual staining were applied to all sam-
ples (Supplementary Table S1). To measure the tissue area, the original images were converted to 8-bit grayscale 
images (ImageJ/Fiji- > Image- > 8-bit), and binary thresholds were then applied. The % positivity of each staining 
in each tumour (regions-of-interest) were quantified as percentages of DAB-stained areas relative to the whole 
tumour area. All raw results and parameters were collected in Excel sheets and can be found in Supplementary 
Table S1.
Spatial quantification with Spa-RQ. A step-by-step installation and user manual for Spa-RQ is included 
in the Spa-RQ-Windows-v1.0.zip and Spa-RQ-MACOS-v1.0.zip (https://bitbucket.org/MagoBitbucket/
spa-rq-tools/downloads). The threshold for each staining was set as the average threshold values of analyses 
performed by three independent experts on multiple ROIs. For the analysis of murine samples, thresholding 
parameters were set manually to match those used in ImageJ/Fiji (Supplementary Table S1). Spa-RQ generates an 
Excel sheet that provides DAB and binary thresholds, and raw results data. A landscape of staining overlap, and 
the segmented images, are automatically saved in the output folder.
Statistical analysis. Data visualisation and statistical analyses were performed with GraphPad Prism7 
(GraphPad Software, Inc. San Diego, USA). For statistical comparisons, a one-way ANOVA multiple comparison 
(Kruskal-Wallis test, nonparametric test) with uncorrected Dunn’s test was used. P values < 0.05 were considered 
significant. Data are presented as individual dots with the mean indicated by bars, or as mean ± SD.
Data availability
The datasets analysed during the current study are available as Supplementary Table S1.
Spa-RQ-V1.0 is freely distributed at https://bitbucket.org/MagoBitbucket/spa-rq-tools as an open-source 
tool. It is written in MATLAB® R2016a with an academic license. The source code, standalone versions, User 
Manual, and additional notes are available at the official repository. Further developing the source code requires 
MATLAB® license. However, Windows and Macintosh standalone compiled versions— that do not require 
license— are also available online.
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